Recursion Pharma Stocks Soar 15.62% with MIT's Boltz-2 Model!

Recursion Pharmaceuticals, Inc. surged 15.62% intraday, following the launch of its Boltz-2 model in collaboration with MIT, marking a significant breakthrough in drug development. The model's accuracy in predicting structural and binding affinity is comparable to physical-based free energy perturbation calculations, but 1000 times faster. The open-source release of Boltz-2 allows scientists to easily adapt to specific types of molecules, accelerating the drug discovery process and addressing a key bottleneck in small molecule discovery.